한글목차

세계의 백혈구성분채집술 시장 규모는 2023년 7,000만 달러에서 2028년 1억 달러에 달할 것으로 예상되며, 8.3%의 CAGR로 추이할 것으로 예측됩니다. 세계의 백혈구성분채집술 시장 규모는 CAGR 38.1%로 추이하여 2023년 2억 달러에서 2028년 10억 2,000만 달러에 이를 것으로 예측됩니다. 세계적으로 백혈병 환자가 증가하고 있으며 임상시험 및 기타 연구 응용 분야에서 백혈구성분채집술 수요가 증가하고 있기 때문에 이 시장은 예측 기간 동안 성장할 것으로 예상됩니다.

용도별로 연구 용도가 더 큰 점유율을 차지했습니다. 세포기반 면역요법의 신흥국 시장의 개척과 의약품 개발에 있어서의 백혈구 유래의 초대세포에 대한 수요 증가는 예측기간 동안 백혈구성분채집술 시장의 성장을 가속하는 주요 요인의 일부입니다.

최종 사용자별로, 2022년에 학술 및 연구 기관 부문은 백혈구 조종 제품 시장에서 가장 큰 점유율을 차지했습니다. 세포 기반 암 치료에 관한 연구를 실시하기 위한 산학 연계가 증가하고 있는 것이 이 최종 사용자 분야의 성장을 견인하고 있습니다.

2022년 아시아 태평양은 예측 기간 동안 최고의 CAGR로 성장했습니다. 앞으로도 가장 급성장하는 지역으로 예상됩니다. 중국에서의 CAR-T 세포요법 연구 증가, 제약·바이오테크놀로지 기업이나 연구기관 증가 등이 시장 성장을 가속하는 요인이 되고 있습니다. 2022년 중국은 아시아 태평양 백혈구 연합 시장에서 가장 큰 점유율을 차지했습니다. 중국의 점유율이 큰 것은 이 나라에 세포 면역요법 기업이 다수 존재하는 것이 주요 요인입니다.

세계의 백혈구성분채집술(Leukapheresis) 시장에 대해 조사했으며, 제품별·적응증별·용도별·최종 사용자별·지역별 동향/시장 진출 기업 개요 등을 정리했습니다.

목차

제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 중요 인사이트

제5장 시장 개요

• 소개
• 시장 역학
• Porter's Five Forces 분석
• 산업 동향
• 기술 분석
• 가격 분석(백혈구성분채집술 시장)
• 주요 컨퍼런스 및 이벤트(2023-2024년)
• 규제 분석(백혈구성분채집술 시장)
• 규제기관, 정부기관, 기타 조직
• 규제 분석(백혈구성분채집술 시장)
• 밸류체인 분석
• 공급망 분석
• 생태계 분석
• HS코드 : 원심장치 및 막분리장치
• 특허 분석
• 주요 이해관계자와 구매 기준
• 사례 연구
• 인접 시장 분석

제6장 백혈구성분채집술 시장, 제품별

• 소개
• 일회용
• 디바이스

제7장 백혈구성분채집술 시장, 용도별

• 소개
• 연구
• 치료

제8장 백혈구성분채집술 시장, 최종 사용자별

• 소개
• 혈액 성분 공급자와 혈액 센터
• 학술연구기관
• 제약회사 및 생명공학 회사
• 병원과 수혈 센터

제9장 백혈구성분채집술 시장, 유형별

• 소개
• 동원형
• 비동원형
• 질병형
• 분리형 PBMCS

제10장 백혈구성분채집술 시장, 적응증별

• 소개
• 급성 림프성 백혈병
• 다발성 골수종
• 비호 지킨 림프종
• 만성 림프성 백혈병
• 췌장암
• 간세포암
• 기타

제11장 백혈구성분채집술 시장, 최종 사용자별

• 소개
• 학술연구기관
• 제약회사 및 바이오테크놀로지 기업
• CRO

제12장 백혈구성분채집술 시장, 지역별

• 소개
• 북미
• 유럽
• 아시아 태평양
• 남미
• 중동 및 아프리카

제13장 경쟁 구도

• 소개
• 주요 진입 기업의 전략/유력기업
• 시장의 주요 진입 기업의 수익 점유율 분석
• 경쟁 벤치마킹
• 시장 점유율 분석(2022년)
• 시장 점유율 분석(2022년)
• 기업 평가 매트릭스(2022년)
• 스타트업/중소기업의 경쟁평가 매트릭스(2022년)
• 경쟁력 평가 매트릭스(2022년)
• 경쟁 시나리오 및 동향

제14장 기업 개요

• 주요 진출 기업
  • TERUMO BCT
  • FRESENIUS SE & CO. KGAA
  • HAEMONETICS CORPORATION
  • ASAHI KASEI CORPORATION
  • MACOPHARMA SA
  • MILTENYI BIOTEC
• 기타 기업
  • GUANGZHOU DAJI MEDICAL SCIENCE AND TECHNOLOGY CO. LTD.
  • MEDICA SPA.
  • PURIBLOOD MEDICAL CO. LTD.
  • BEIJING ZKSK TECHNOLOGY CO. LTD.
  • SB-KAWASUMI LABORATORIES, INC.
  • NIKKISO CO., LTD.
  • PALL CORPORATION
• 주요 진입 기업
  • CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
  • DISCOVERY LIFE SCIENCES, INC.
  • BIOIVT
  • PRECISION FOR MEDICINE, INC.
  • STEMEXPRESS, LLC
• 기타 기업
  • LONZA GROUP AG
  • CALTAG MEDSYSTEMS LIMITED
  • ZENBIO, INC.
  • STEMCELL TECHNOLOGIES
  • TRINA BIOREACTIVES AG
  • ACCEGEN
  • FIRST CHOICE BIO LLC

제15장 부록

영문목차

The global leukapheresis products market is predicted to reach USD 100 million by 2028 from USD 70 million in 2023, at a CAGR of 8.3%. The global leukopaks market is predicted to reach USD 1020 million by 2028 from USD 200 million in 2023, at a CAGR of 38.1%. Due to the cases of leukemia rising globally, and rising need for leukopaks in clinical trials and other research applications, the leukapheresis market is expected to grow in the forecast period.

"The research applications accounted for a larger share of the leukapheresis products market."

By, application, the leukpaheresis products market is segmented into research applications and therapeutic applications. The research applications segment accounted for the larger share of the leukapheresis products market in 2022. The growing development of cell-based immunotherapies and rising demand for leukapheresis-derived primary cells in drug development are some of the major factors driving the growth of the leukapheresis products market during the forecast period.

"The academic & research institutes segment accounted for the largest share of the leukopaks market."

By end user, the leukopaks market is segmented into academic & research institutes, pharmaceutical & biotechnology companies, and contract research organizations. In 2022, the academic & research institutes segment accounted for the largest share of the leukapheresis products market. The increasing number of industry-academic partnerships for conducting research on cell-based cancer therapies is driving the growth of this end-user segment.

"Asia Pacific will grow at highest CAGR during the forecast period."

In 2022, Asia Pacific will grow at highest CAGR during the forecast period. The Asia Pacific region is expected to be the fastest growing region in the forecast period. The increasing CAR-T cell therapy research and rising number of pharma & biotech companies and research institutes in China are some of the factors driving market growth. In 2022, China accounted for the largest share of the Asia Pacific leukopaks market. The large share of China can be attributed mainly to the presence of a number of cellular immunotherapy companies in the country.

The break-up of the profile of primary participants in the leukapheresis products market: Supply-side

• By Company Type (Supply-side): Tier 1: 35%, Tier 2: 30%, and Tier 3: 35%
• By Designation: C-level: 30%, Director-level: 30%, and Others: 40%
• By Region: North America: 45%, Europe: 25%, Asia-Pacific: 20%, and Rest of the World: 10%

The break-up of the profile of primary participants in the leukopaks market: Supply-side

• By Company Type (Supply-side): Tier 1: 44%, Tier 2: 36%, and Tier 3: 20%
• By Designation: C-level: 44%, Director-level: 33%, and Others: 23%
• By Region: North America: 40%, Europe: 25%, Asia-Pacific: 20%, and Rest of the World: 15%

Prominent players in the leukapheresis products market include Asahi Kasei Corporation (Japan), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (US), Terumo BCT, Inc. (US), Macopharma SA (France), and Miltenyi Biotec (Germany).

Some prominent players in the leukopaks market are Discovery Life Sciences (US), StemExpress, LLC (US), Charles River Laboratories International, Inc. (US), Caltag Medsystems Limited (UK), Lonza Group AG (Switzerland), and ZenBio (US).

Research Coverage:

The report analyzes the leukapheresis market and aims at estimating the market size and future growth potential of this market based on various segments such as product, and region. The report also includes competitive analysis of the key players in this market along with their company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the Report

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall leukapheresis market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

This report provides insights into the following pointers:

• Analysis of key drivers (rising incidence and prevalence of leukemia, increasing number of blood donations, increased demand for leukopaks in clinical research), restraints (high cost of therapeutic leukapheresis and leukopaks, stringent donor recruitment criteria, complications associated with therapeutic leukapheresis), opportunities (leukapheresis for pediatric patients, emerging economies with investments from academic institutes, pharma-biotech companies, and leading players), and challenges (blood transfusion safety in emerging countries) influencing the growth of the leukapheresis market
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the leukapheresis market
• Market Development: Comprehensive information on the lucrative emerging markets by type, usage, end user and region.
• Market Diversification: Exhaustive information about new products or product enhancements, growing geographies, recent developments, and investments in the global leukapheresis market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, competitive leadership mapping, and capabilities of leading players like Asahi Kasei Corporation (Japan), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (US), Terumo BCT, Inc. (US), Macopharma SA (France), and Miltenyi Biotec (Germany) in the global leukapheresis market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
  • 1.2.1 TYPE
  • 1.2.2 APPLICATION
  • 1.2.3 END USER
  • 1.2.4 INCLUSIONS AND EXCLUSIONS
• 1.3 MARKET SCOPE
  • 1.3.1 MARKETS COVERED
  • 1.3.2 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
  • TABLE 1 STANDARD CURRENCY CONVERSION RATES
• 1.5 STAKEHOLDERS
• 1.6 SUMMARY OF CHANGES
• 1.7 RECESSION IMPACT

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • FIGURE 1 RESEARCH DESIGN
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
  • FIGURE 2 PRIMARY SOURCES
    • 2.1.2.1 Key data from primary sources
    • 2.1.2.2 Insights from primary experts
  • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS (LEUKAPHERESIS PRODUCTS AND LEUKOPAKS MARKET)
  • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION (LEUKAPHERESIS PRODUCTS MARKET)
  • FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, AND REGION (LEUKAPHERESIS PRODUCTS MARKET)
  • FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION (LEUKOPAKS MARKET)
  • FIGURE 7 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, AND REGION (LEUKOPAKS MARKET)
• 2.2 MARKET SIZE ESTIMATION: LEUKAPHERESIS PRODUCTS MARKET
  • FIGURE 8 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
  • FIGURE 9 REVENUE SHARE ANALYSIS ILLUSTRATION: TERUMO CORPORATION (2022)
  • FIGURE 10 REVENUE ANALYSIS OF TOP FOUR COMPANIES: LEUKAPHERESIS PRODUCTS MARKET (2022)
  • FIGURE 11 DEMAND-SIDE APPROACH: LEUKAPHERESIS PRODUCTS MARKET (2022)
  • FIGURE 12 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2023-2028)
  • FIGURE 13 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS (LEUKAPHERESIS PRODUCTS MARKET)
  • FIGURE 14 TOP-DOWN APPROACH
• 2.3 MARKET SIZE ESTIMATION: LEUKOPAKS MARKET
  • FIGURE 15 VOLUME ESTIMATION OF LEUKOPAKS MARKET
  • FIGURE 16 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS (LEUKOPAKS MARKET)
  • FIGURE 17 TOP-DOWN APPROACH
• 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
  • FIGURE 18 MARKET DATA TRIANGULATION METHODOLOGY
• 2.5 MARKET SHARE ANALYSIS
• 2.6 RESEARCH ASSUMPTIONS
• 2.7 RISK ASSESSMENT
  • TABLE 2 RISK ASSESSMENT: LEUKAPHERESIS PRODUCTS AND LEUKOPAKS MARKETS
• 2.8 METHODOLOGY-RELATED LIMITATIONS
• 2.9 RECESSION IMPACT ANALYSIS

3 EXECUTIVE SUMMARY

• FIGURE 19 LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
• FIGURE 20 LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
• FIGURE 21 LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
• FIGURE 22 LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
• FIGURE 23 LEUKOPAKS MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
• FIGURE 24 LEUKOPAKS MARKET, BY INDICATION, 2023 VS. 2028 (USD MILLION)
• FIGURE 25 LEUKOPAKS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
• FIGURE 26 GEOGRAPHIC SNAPSHOT: LEUKAPHERESIS PRODUCTS MARKET
• FIGURE 27 GEOGRAPHIC SNAPSHOT: LEUKOPAKS MARKET

4 PREMIUM INSIGHTS

• 4.1 LEUKAPHERESIS PRODUCTS MARKET: OVERVIEW
  • FIGURE 28 INCREASING INCIDENCE AND PREVALENCE OF LEUKEMIA TO DRIVE MARKET
• 4.2 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE AND COUNTRY
  • FIGURE 29 DISPOSABLES TO DOMINATE NORTH AMERICAN LEUKAPHERESIS PRODUCTS MARKET IN 2022
• 4.3 LEUKAPHERESIS PRODUCTS MARKET: GEOGRAPHIC MIX
  • FIGURE 30 CHINA TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
• 4.4 LEUKAPHERESIS PRODUCTS MARKET: REGIONAL MIX
  • FIGURE 31 NORTH AMERICA DOMINATED MARKET IN 2022
• 4.5 LEUKOPAKS MARKET: OVERVIEW
  • FIGURE 32 RISING DEMAND FOR LEUKOPAKS FOR USE IN RESEARCH APPLICATIONS TO DRIVE MARKET
• 4.6 NORTH AMERICA: LEUKOPAKS MARKET, BY PRODUCT AND COUNTRY
  • FIGURE 33 MOBILIZED LEUKOPAKS COMMANDED LARGEST SHARE OF MARKET IN 2022
• 4.7 LEUKOPAKS MARKET: GEOGRAPHIC MIX
  • FIGURE 34 CHINA TO RECORD HIGHEST GROWTH DURING FORECAST PERIOD
• 4.8 LEUKOPAKS MARKET: REGIONAL MIX
  • FIGURE 35 ASIA PACIFIC MARKET TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • FIGURE 36 LEUKAPHERESIS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • 5.2.1 DRIVERS
    • 5.2.1.1 Rising incidence and prevalence of leukemia
  • FIGURE 37 ESTIMATED NUMBER OF NEW LEUKEMIA CASES, BY REGION (2020-2040)
  • FIGURE 38 ESTIMATED NUMBER OF LEUKEMIA DEATHS, BY REGION (2020-2040)
    • 5.2.1.2 Increasing blood donation
    • 5.2.1.3 Growing demand for leukopaks in clinical research
  • FIGURE 39 GROWTH IN NUMBER OF CAR-T CLINICAL TRIALS, 2009-2020
  • FIGURE 40 NUMBER OF CAR-T THERAPY CLINICAL TRIALS: US VS. CHINA, 2022
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High cost of therapeutic leukapheresis and leukopaks
  • TABLE 3 COST OF LEUKOPAKS, BY TYPE
    • 5.2.2.2 Stringent donor recruitment criteria
  • TABLE 4 DONOR SELECTION CRITERIA
  • TABLE 5 FREQUENCY OF BLOOD DONATION FROM HEALTHY DONORS
    • 5.2.2.3 Dearth of skilled professionals
    • 5.2.2.4 Complications associated with therapeutic leukapheresis
    • 5.2.2.5 Long duration of procedure
    • 5.2.2.6 High cost of cellular immunotherapies and lack of favorable reimbursement
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Growing focus on leukapheresis for pediatric patients
    • 5.2.3.2 Increasing investments in CAR-T therapies in emerging economies
    • 5.2.3.3 Gaps in current leukapheresis technologies
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Concerns related to safety of blood transfusion in emerging economies
• 5.3 PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 41 PORTER'S FIVE FORCES ANALYSIS: LEUKAPHERESIS MARKET
  • TABLE 6 LEUKAPHERESIS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • 5.3.1 THREAT FROM NEW ENTRANTS
  • 5.3.2 THREAT FROM SUBSTITUTES
  • 5.3.3 BARGAINING POWER OF SUPPLIERS
  • 5.3.4 BARGAINING POWER OF BUYERS
  • 5.3.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.4 INDUSTRY TRENDS
  • 5.4.1 INCREASING COLLABORATIONS BETWEEN PHARMA AND BIOTECH COMPANIES
  • TABLE 7 RECENT DEVELOPMENTS RELATED TO CAR-T THERAPY
  • 5.4.2 INTRODUCTION OF CUSTOMIZABLE CRYOPRESERVED LEUKOPAKS
• 5.5 TECHNOLOGY ANALYSIS
  • 5.5.1 KEY TECHNOLOGIES
    • 5.5.1.1 Centrifugal-based leukapheresis
    • 5.5.1.2 Membrane-based leukapheresis
  • TABLE 8 MATERIALS USED FOR LEUKOCYTE FILTRATION AND SURFACE MODIFICATION TECHNIQUES APPLIED FOR ENHANCED SEPARATION
  • 5.5.2 EMERGING TECHNOLOGIES
    • 5.5.2.1 Adsorption-based leukapheresis
    • 5.5.2.2 Microfluidic devices for leukapheresis
    • 5.5.2.3 Integration of AI in leukapheresis treatment
• 5.6 PRICING ANALYSIS (LEUKOPAKS MARKET)
  • TABLE 9 ASP OF NON-MOBILIZED LEUKOPAKS
  • TABLE 10 ASP OF MOBILIZED LEUKOPAKS
  • TABLE 11 ASP OF MOBILIZED ISOLATED CELLS
• 5.7 KEY CONFERENCES AND EVENTS, 2023-2024
  • TABLE 12 LEUKAPHERESIS MARKET: CONFERENCES AND EVENTS
• 5.8 REGULATORY ANALYSIS (LEUKAPHERESIS PRODUCTS MARKET)
  • 5.8.1 NORTH AMERICA
    • 5.8.1.1 US
    • 5.8.1.2 Canada
  • 5.8.2 EUROPE
  • 5.8.3 ASIA PACIFIC
    • 5.8.3.1 Japan
    • 5.8.3.2 China
• 5.9 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 13 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 14 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 15 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 16 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 17 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.10 REGULATORY ANALYSIS (LEUKOPAKS MARKET)
  • 5.10.1 US
  • TABLE 18 LIST OF FDA-APPROVED CAR-T THERAPEUTICS
  • 5.10.2 EUROPE
  • 5.10.3 JAPAN
  • 5.10.4 INDIA
• 5.11 VALUE CHAIN ANALYSIS
  • FIGURE 42 VALUE CHAIN: LEUKAPHERESIS MARKET (LEUKAPHERESIS SYSTEMS)
• 5.12 SUPPLY CHAIN ANALYSIS
  • FIGURE 43 LEUKAPHERESIS MARKET: STAKEHOLDERS IN SUPPLY CHAIN
• 5.13 ECOSYSTEM ANALYSIS
  • FIGURE 44 LEUKAPHERESIS MARKET: ECOSYSTEM MAP
  • TABLE 19 LEUKAPHERESIS MARKET: ECOSYSTEM
• 5.14 HS CODES: CENTRIFUGAL DEVICES AND MEMBRANE SEPARATORS
• 5.15 PATENT ANALYSIS
  • 5.15.1 PATENT PUBLICATION TRENDS IN LEUKAPHERESIS PRODUCTS MARKET
  • FIGURE 45 GLOBAL PATENT PUBLICATION TRENDS IN LEUKAPHERESIS PRODUCTS MARKET, JANUARY 2019-AUGUST 2023
  • 5.15.2 PATENT PUBLICATION TRENDS IN LEUKOPAKS MARKET
  • FIGURE 46 GLOBAL PATENT PUBLICATION TRENDS IN LEUKOPAKS MARKET, JANUARY 2019-AUGUST 2023
  • 5.15.3 TOP APPLICANTS FOR LEUKAPHERESIS PRODUCT PATENTS
  • FIGURE 47 TOP APPLICANTS FOR LEUKAPHERESIS PRODUCT PATENTS, JANUARY 2019-AUGUST 2023
  • 5.15.4 TOP APPLICANTS FOR LEUKOPAK PATENTS
  • FIGURE 48 TOP APPLICANTS FOR LEUKOPAK PATENTS, JANUARY 2019-AUGUST 2023
  • 5.15.5 JURISDICTION ANALYSIS: TOP COUNTRIES FOR LEUKAPHERESIS MARKET PATENTS
  • FIGURE 49 JURISDICTION ANALYSIS: TOP COUNTRIES FOR LEUKAPHERESIS PATENTS, JANUARY 2019-AUGUST 2023
  • FIGURE 50 JURISDICTION ANALYSIS: TOP COUNTRIES FOR LEUKOPAK PATENTS, JANUARY 2019-AUGUST 2023
  • 5.15.6 TOP PATENT APPLICANTS/OWNERS
  • FIGURE 51 TOP APPLICANTS AND OWNERS FOR LEUKAPHERESIS PRODUCT PATENTS, JANUARY 2019-AUGUST 2023
  • FIGURE 52 TOP APPLICANTS AND OWNERS FOR LEUKOPAK PATENTS, JANUARY 2019-AUGUST 2023
  • TABLE 20 LEUKAPHERESIS PRODUCTS MARKET: MAJOR PATENTS (2020-2022)
  • TABLE 21 LEUKOPAKS MARKET: MAJOR PATENTS (2019-2022)
• 5.16 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • FIGURE 53 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR LEUKAPHERESIS PRODUCTS AND LEUKOPAKS
  • TABLE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR LEUKAPHERESIS PRODUCTS AND LEUKOPAKS
  • 5.16.2 BUYING CRITERIA
  • FIGURE 54 KEY BUYING CRITERIA FOR LEUKAPHERESIS PRODUCTS AND LEUKOPAKS
  • TABLE 23 KEY BUYING CRITERIA FOR LEUKAPHERESIS PRODUCTS AND LEUKOPAKS
• 5.17 CASE STUDIES
  • TABLE 24 CASE STUDY 1: ESTIMATING MARKET SIZE OF LEUKAPHERESIS PRODUCTS AND MARKET SHARE ANALYSIS FOR KEY PRODUCTS AT COUNTRY LEVEL
  • TABLE 25 CASE STUDY 2: ESTIMATING MARKET SIZE OF LEUKOPAKS AND MARKET SHARE ANALYSIS FOR KEY PRODUCTS AT COUNTRY LEVEL
• 5.18 ADJACENT MARKET ANALYSIS
  • 5.18.1 PLASMA FRACTIONATION MARKET
  • FIGURE 55 PLASMA FRACTIONATION MARKET OVERVIEW
  • 5.18.2 APHERESIS MARKET
  • FIGURE 56 APHERESIS MARKET OVERVIEW

6 LEUKAPHERESIS PRODUCTS MARKET, BY TYPE

• 6.1 INTRODUCTION
  • TABLE 26 LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 27 LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
• 6.2 DISPOSABLES
  • 6.2.1 RECURRENT DEMAND TO BOOST SEGMENT
  • TABLE 28 LEUKOREDUCTION FILTER MANUFACTURERS
  • TABLE 29 LEUKAPHERESIS COLUMN AND CELL SEPARATOR MANUFACTURERS
  • TABLE 30 DISPOSABLES: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
• 6.3 DEVICES
  • TABLE 31 DEVICES: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 32 DEVICES: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.3.1 CENTRIFUGAL DEVICES
    • 6.3.1.1 Increasing installation in hospitals to drive market
  • TABLE 33 CENTRIFUGAL DEVICES AVAILABLE
  • TABLE 34 CENTRIFUGAL DEVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.3.2 MEMBRANE SEPARATORS
    • 6.3.2.1 Difficulty in separating large volumes of plasma to limit market
  • TABLE 35 MEMBRANE SEPARATORS AVAILABLE
  • TABLE 36 MEMBRANE SEPARATORS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)

7 LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION

• 7.1 INTRODUCTION
  • TABLE 37 LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
• 7.2 RESEARCH APPLICATIONS
  • 7.2.1 GROWING NUMBER OF CLINICAL TRIALS TO DRIVE SEGMENT
  • TABLE 38 COMPANIES DEVELOPING FDA-APPROVED CAR-T CELL THERAPIES
  • TABLE 39 RESEARCH APPLICATIONS: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
• 7.3 THERAPEUTIC APPLICATIONS
  • 7.3.1 RISING ADOPTION OF LEUKAPHERESIS FOR LEUKEMIA TREATMENT TO FUEL MARKET
  • TABLE 40 THERAPEUTIC APPLICATIONS: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)

8 LEUKAPHERESIS PRODUCTS MARKET, BY END USER

• 8.1 INTRODUCTION
  • TABLE 41 LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021-2028 (USD MILLION)
• 8.2 BLOOD COMPONENT PROVIDERS & BLOOD CENTERS
  • 8.2.1 INCREASING BLOOD DONATION TO DRIVE MARKET
  • TABLE 42 BLOOD COMPONENT PROVIDERS & BLOOD CENTERS: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
• 8.3 ACADEMIC & RESEARCH INSTITUTES
  • 8.3.1 COLLABORATIONS WITH PHARMACEUTICAL COMPANIES TO BOOST MARKET
  • TABLE 43 ACADEMIC & RESEARCH INSTITUTES: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
• 8.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 8.4.1 INCREASING NUMBER OF CLINICAL TRIALS TO DRIVE SEGMENT
  • TABLE 44 PHARMA-BIOTECH COMPANIES DEVELOPING CAR-T CELL TECHNOLOGIES
  • TABLE 45 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
• 8.5 HOSPITALS & TRANSFUSION CENTERS
  • 8.5.1 GROWING NEED FOR TRANSFUSIONS TO PROPEL MARKET
  • TABLE 46 HOSPITALS & TRANSFUSION CENTERS: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)

9 LEUKOPAKS MARKET, BY TYPE

• 9.1 INTRODUCTION
  • TABLE 47 LEUKOPAKS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 48 LEUKOPAKS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
• 9.2 MOBILIZED LEUKOPAKS
  • 9.2.1 INCREASING USE IN CLINICAL RESEARCH TO DRIVE MARKET
  • TABLE 49 TREATMENT REGIMENS FOR DEVELOPMENT OF MOBILIZED LEUKOPAKS
  • TABLE 50 MOBILIZED LEUKOPAKS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 51 MOBILIZED LEUKOPAKS MARKET, BY REGION, 2021-2028 (UNITS)
• 9.3 NON-MOBILIZED LEUKOPAKS
  • 9.3.1 LOW COST TO PROPEL MARKET
  • TABLE 52 NUMBER OF CELLS IN NON-MOBILIZED LEUKOPAKS
  • TABLE 53 COMPARATIVE ANALYSIS OF MOBILIZED AND NON-MOBILIZED LEUKOPAKS
  • TABLE 54 COMPOSITION OF MOBILIZED AND NON-MOBILIZED LEUKOPAKS
  • TABLE 55 NON-MOBILIZED LEUKOPAKS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 56 NON-MOBILIZED LEUKOPAKS MARKET, BY REGION, 2021-2028 (UNITS)
• 9.4 DISEASED LEUKOPAKS
  • 9.4.1 RISING USE FOR CELL INTERACTION AND DRUG TOXICITY STUDIES TO BOOST MARKET
  • TABLE 57 DISEASED LEUKOPAKS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 58 DISEASED LEUKOPAKS MARKET, BY REGION, 2021-2028 (UNITS)
• 9.5 ISOLATED PBMCS
  • 9.5.1 INCREASING RESEARCH FOCUS ON CELL-BASED THERAPIES TO FUEL MARKET
  • TABLE 59 IMMUNE CELL TYPES AND TARGETED DISEASES
  • TABLE 60 ISOLATED PBMCS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 61 ISOLATED PBMCS MARKET, BY REGION, 2021-2028 (UNITS)

10 LEUKOPAKS MARKET, BY INDICATION

• 10.1 INTRODUCTION
  • FIGURE 57 NUMBER OF GLOBAL CLINICAL TRIALS WITH CHIMERIC ANTIGEN RECEPTOR (CAR) CELLS
  • TABLE 62 LEUKOPAKS MARKET, BY INDICATION, 2021-2028 (USD MILLION)
• 10.2 ACUTE LYMPHOCYTIC LEUKEMIA
  • 10.2.1 RISING INCIDENCE OF DISEASE TO DRIVE MARKET
  • TABLE 63 ACUTE LYMPHOCYTIC LEUKEMIA: LEUKOPAKS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
• 10.3 MULTIPLE MYELOMA
  • 10.3.1 RISING DIAGNOSIS RATE TO FUEL SEGMENT
  • FIGURE 58 INCIDENCE OF MULTIPLE MYELOMA IN 2020
  • TABLE 64 MULTIPLE MYELOMA: LEUKOPAKS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
• 10.4 NON-HODGKIN'S LYMPHOMA
  • 10.4.1 DEVELOPMENT OF NOVEL THERAPIES TO BOOST MARKET
  • TABLE 65 NON-HODGKIN'S LYMPHOMA: LEUKOPAKS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
• 10.5 CHRONIC LYMPHOCYTIC LEUKEMIA
  • 10.5.1 RISING NUMBER OF CASES TO PROPEL MARKET
  • TABLE 66 CHRONIC LYMPHOCYTIC LEUKEMIA: LEUKOPAKS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
• 10.6 PANCREATIC CANCER
  • 10.6.1 DEVELOPMENT OF NEW DIAGNOSTIC TECHNIQUES TO DRIVE SEGMENT
  • FIGURE 59 INCIDENCE OF PANCREATIC CANCER IN 2020
  • TABLE 67 PANCREATIC CANCER: LEUKOPAKS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
• 10.7 HEPATOCELLULAR CARCINOMA
  • 10.7.1 INCREASING INCIDENCE OF VIRAL HEPATITIS TO FUEL SEGMENT
  • TABLE 68 HEPATOCELLULAR CARCINOMA: LEUKOPAKS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
• 10.8 OTHER INDICATIONS
  • TABLE 69 OTHER INDICATIONS: LEUKOPAKS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)

11 LEUKOPAKS MARKET, BY END USER

• 11.1 INTRODUCTION
  • TABLE 70 LEUKOPAKS MARKET, BY END USER, 2021-2028 (USD MILLION)
• 11.2 ACADEMIC & RESEARCH INSTITUTES
  • 11.2.1 INCREASING INDUSTRY-ACADEMIC RESEARCH PARTNERSHIPS TO DRIVE MARKET
  • TABLE 71 ACADEMIC & RESEARCH INSTITUTES: LEUKOPAKS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
• 11.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 11.3.1 RISING DEMAND FOR TARGET DRUG DEVELOPMENT TO PROPEL MARKET
  • FIGURE 60 PERCENTAGE OF GLOBAL CAR-T DRUGS IN US AND CHINA, BY YEAR OF FIRST IDENTIFICATION/REPORT
  • TABLE 72 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: LEUKOPAKS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
• 11.4 CONTRACT RESEARCH ORGANIZATIONS
  • 11.4.1 INCREASING CLINICAL TRIAL SPONSORSHIP TO DRIVE MARKET
  • TABLE 73 CONTRACT RESEARCH ORGANIZATIONS: LEUKOPAKS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)

12 LEUKAPHERESIS MARKET, BY REGION

• 12.1 INTRODUCTION
  • FIGURE 61 LEUKAPHERESIS PRODUCTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
  • TABLE 74 LEUKAPHERESIS PRODUCTS MARKET, BY REGION, 2021-2028 (USD MILLION)
  • FIGURE 62 LEUKOPAKS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
  • TABLE 75 LEUKOPAKS MARKET, BY REGION, 2021-2028 (USD MILLION)
• 12.2 NORTH AMERICA
  • 12.2.1 RECESSION IMPACT: NORTH AMERICA
  • FIGURE 63 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET SNAPSHOT
  • TABLE 76 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 77 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 78 NORTH AMERICA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 79 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 80 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 81 NORTH AMERICA: LEUKOPAKS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 82 NORTH AMERICA: LEUKOPAKS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 83 NORTH AMERICA: LEUKOPAKS MARKET, BY INDICATION, 2021-2028 (USD MILLION)
  • TABLE 84 NORTH AMERICA: LEUKOPAKS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 12.2.2 US
    • 12.2.2.1 Presence of leading pharmaceutical and biotechnology companies to drive market
  • TABLE 85 DIAGNOSIS-RELATED GROUP REIMBURSEMENT (DRG)
  • TABLE 86 US: KEY MACROINDICATORS
  • TABLE 87 US: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 88 US: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 89 US: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 90 US: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 91 US: LEUKOPAKS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 92 US: LEUKOPAKS MARKET, BY INDICATION, 2021-2028 (USD MILLION)
  • TABLE 93 US: LEUKOPAKS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 12.2.3 CANADA
    • 12.2.3.1 Rising prevalence of blood cancer to stimulate market growth
  • TABLE 94 CANADA: KEY MACROINDICATORS
  • TABLE 95 CANADA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 96 CANADA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 97 CANADA: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 98 CANADA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 99 CANADA: LEUKOPAKS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 100 CANADA: LEUKOPAKS MARKET, BY INDICATION, 2021-2028 (USD MILLION)
  • TABLE 101 CANADA: LEUKOPAKS MARKET, BY END USER, 2021-2028 (USD MILLION)
• 12.3 EUROPE
  • 12.3.1 RECESSION IMPACT: EUROPE
  • FIGURE 64 EUROPE: LEUKAPHERESIS PRODUCTS MARKET SNAPSHOT
  • TABLE 102 EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 103 EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 104 EUROPE: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 105 EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 106 EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 107 EUROPE: LEUKOPAKS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 108 EUROPE: LEUKOPAKS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 109 EUROPE: LEUKOPAKS MARKET, BY INDICATION, 2021-2028 (USD MILLION)
  • TABLE 110 EUROPE: LEUKOPAKS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 12.3.2 UK
    • 12.3.2.1 Rising awareness of cell-based therapies to propel market
  • TABLE 111 UK: KEY MACROINDICATORS
  • TABLE 112 UK: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 113 UK: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 114 UK: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 115 UK: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 116 UK: LEUKOPAKS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 117 UK: LEUKOPAKS MARKET, BY INDICATION, 2021-2028 (USD MILLION)
  • TABLE 118 UK: LEUKOPAKS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 12.3.3 GERMANY
    • 12.3.3.1 Increasing research on cancer immunotherapies to boost market
  • TABLE 119 GERMANY: KEY MACROINDICATORS
  • TABLE 120 GERMANY: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 121 GERMANY: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 122 GERMANY: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 123 GERMANY: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 124 GERMANY: LEUKOPAKS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 125 GERMANY: LEUKOPAKS MARKET, BY INDICATION, 2021-2028 (USD MILLION)
  • TABLE 126 GERMANY: LEUKOPAKS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 12.3.4 SPAIN
    • 12.3.4.1 Rising focus on development of novel CAR-T cell therapies to fuel market
  • TABLE 127 SPAIN: KEY MACROINDICATORS
  • TABLE 128 SPAIN: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 129 SPAIN: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 130 SPAIN: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 131 SPAIN: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 132 SPAIN: LEUKOPAKS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 133 SPAIN: LEUKOPAKS MARKET, BY INDICATION, 2021-2028 (USD MILLION)
  • TABLE 134 SPAIN: LEUKOPAKS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 12.3.5 FRANCE
    • 12.3.5.1 Government healthcare initiatives to drive market
  • TABLE 135 FRANCE: KEY MACROINDICATORS
  • TABLE 136 FRANCE: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 137 FRANCE: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 138 FRANCE: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 139 FRANCE: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 140 FRANCE: LEUKOPAKS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 141 FRANCE: LEUKOPAKS MARKET, BY INDICATION, 2021-2028 (USD MILLION)
  • TABLE 142 FRANCE: LEUKOPAKS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 12.3.6 ITALY
    • 12.3.6.1 Increasing adoption of cell-based therapies to boost market
  • TABLE 143 ITALY: COMMERCIAL CAR-T CELL THERAPIES APPROVED BY EMA (2022)
  • TABLE 144 ITALY: KEY MACROINDICATORS
  • TABLE 145 ITALY: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 146 ITALY: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 147 ITALY: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 148 ITALY: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 149 ITALY: LEUKOPAKS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 150 ITALY: LEUKOPAKS MARKET, BY INDICATION, 2021-2028 (USD MILLION)
  • TABLE 151 ITALY: LEUKOPAKS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 12.3.7 REST OF EUROPE
  • TABLE 152 REST OF EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 153 REST OF EUROPE: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 154 REST OF EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 155 REST OF EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 156 REST OF EUROPE: LEUKOPAKS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 157 REST OF EUROPE: LEUKOPAKS MARKET, BY INDICATION, 2021-2028 (USD MILLION)
  • TABLE 158 REST OF EUROPE: LEUKOPAKS MARKET, BY END USER, 2021-2028 (USD MILLION)
• 12.4 ASIA PACIFIC
  • 12.4.1 RECESSION IMPACT: ASIA PACIFIC
  • FIGURE 65 ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET SNAPSHOT
  • TABLE 159 ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 160 ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 161 ASIA PACIFIC: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 162 ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 163 ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 164 ASIA PACIFIC: LEUKOPAKS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 165 ASIA PACIFIC: LEUKOPAKS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 166 ASIA PACIFIC: LEUKOPAKS MARKET, BY INDICATION, 2021-2028 (USD MILLION)
  • TABLE 167 ASIA PACIFIC: LEUKOPAKS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 12.4.2 CHINA
    • 12.4.2.1 Growing awareness of benefits of leukapheresis to drive market
  • FIGURE 66 CHINA: NUMBER OF CAR-T BASED CLINICAL TRIALS REGISTERED (2013-2020)
  • TABLE 168 CHINA: KEY MACROINDICATORS
  • TABLE 169 CHINA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 170 CHINA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 171 CHINA: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 172 CHINA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 173 CHINA: LEUKOPAKS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 174 CHINA: LEUKOPAKS MARKET, BY INDICATION, 2021-2028 (USD MILLION)
  • TABLE 175 CHINA: LEUKOPAKS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 12.4.3 JAPAN
    • 12.4.3.1 Focus on development of cell therapies to boost market
  • TABLE 176 JAPAN: KEY MACROINDICATORS
  • TABLE 177 JAPAN: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 178 JAPAN: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 179 JAPAN: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 180 JAPAN: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 181 JAPAN: LEUKOPAKS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 182 JAPAN: LEUKOPAKS MARKET, BY INDICATION, 2021-2028 (USD MILLION)
  • TABLE 183 JAPAN: LEUKOPAKS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 12.4.4 INDIA
    • 12.4.4.1 Rising government investment in healthcare to drive market growth
  • TABLE 184 INDIA: KEY MACROINDICATORS
  • TABLE 185 INDIA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 186 INDIA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 187 INDIA: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 188 INDIA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 189 INDIA: LEUKOPAKS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 190 INDIA: LEUKOPAKS MARKET, BY INDICATION, 2021-2028 (USD MILLION)
  • TABLE 191 INDIA: LEUKOPAKS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 12.4.5 AUSTRALIA
    • 12.4.5.1 Increasing incidence of blood cancer to drive market
  • TABLE 192 AUSTRALIA: KEY MACROINDICATORS
  • TABLE 193 AUSTRALIA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 194 AUSTRALIA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 195 AUSTRALIA: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 196 AUSTRALIA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 197 AUSTRALIA: LEUKOPAKS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 198 AUSTRALIA: LEUKOPAKS MARKET, BY INDICATION, 2021-2028 (USD MILLION)
  • TABLE 199 AUSTRALIA: LEUKOPAKS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 12.4.6 SOUTH KOREA
    • 12.4.6.1 Increasing research in cell therapy to fuel market growth
  • TABLE 200 SOUTH KOREA: KEY MACROINDICATORS
  • TABLE 201 SOUTH KOREA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 202 SOUTH KOREA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 203 SOUTH KOREA: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 204 SOUTH KOREA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 205 SOUTH KOREA: LEUKOPAKS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 206 SOUTH KOREA: LEUKOPAKS MARKET, BY INDICATION, 2021-2028 (USD MILLION)
  • TABLE 207 SOUTH KOREA: LEUKOPAKS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 12.4.7 REST OF ASIA PACIFIC
  • TABLE 208 REST OF ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 209 REST OF ASIA PACIFIC: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 210 REST OF ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 211 REST OF ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 212 REST OF ASIA PACIFIC: LEUKOPAKS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 213 REST OF ASIA PACIFIC: LEUKOPAKS MARKET, BY INDICATION, 2021-2028 (USD MILLION)
  • TABLE 214 REST OF ASIA PACIFIC: LEUKOPAKS MARKET, BY END USER, 2021-2028 (USD MILLION)
• 12.5 LATIN AMERICA
  • 12.5.1 RECESSION IMPACT: LATIN AMERICA
  • TABLE 215 LATIN AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 216 LATIN AMERICA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 217 LATIN AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 218 LATIN AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 219 LATIN AMERICA: LEUKOPAKS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 220 LATIN AMERICA: LEUKOPAKS MARKET, BY INDICATION, 2021-2028 (USD MILLION)
  • TABLE 221 LATIN AMERICA: LEUKOPAKS MARKET, BY END USER, 2021-2028 (USD MILLION)
• 12.6 MIDDLE EAST & AFRICA
  • 12.6.1 RECESSION IMPACT: MIDDLE EAST & AFRICA
  • TABLE 222 MIDDLE EAST & AFRICA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 223 MIDDLE EAST & AFRICA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 224 MIDDLE EAST & AFRICA: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 225 MIDDLE EAST & AFRICA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 226 MIDDLE EAST & AFRICA: LEUKOPAKS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 227 MIDDLE EAST & AFRICA: LEUKOPAKS MARKET, BY INDICATION, 2021-2028 (USD MILLION)
  • TABLE 228 MIDDLE EAST & AFRICA: LEUKOPAKS MARKET, BY END USER, 2021-2028 (USD MILLION)

13 COMPETITIVE LANDSCAPE

• 13.1 INTRODUCTION
• 13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN LEUKAPHERESIS PRODUCTS MARKET
  • 13.2.2 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN LEUKOPAKS MARKET
• 13.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
  • FIGURE 67 LEUKAPHERESIS MARKET: REVENUE SHARE ANALYSIS OF TOP FOUR MARKET PLAYERS
• 13.4 COMPETITIVE BENCHMARKING (LEUKAPHERESIS PRODUCTS MARKET)
  • TABLE 229 OVERALL COMPANY FOOTPRINT
  • TABLE 230 COMPANY END USER FOOTPRINT
  • TABLE 231 COMPANY APPLICATION FOOTPRINT
  • TABLE 232 COMPANY REGION FOOTPRINT
• 13.5 MARKET SHARE ANALYSIS (LEUKAPHERESIS PRODUCTS, 2022)
  • TABLE 233 LEUKAPHERESIS PRODUCTS MARKET: DEGREE OF COMPETITION
  • FIGURE 68 LEUKAPHERESIS PRODUCTS MARKET SHARE, BY KEY PLAYER (2022)
• 13.6 MARKET SHARE ANALYSIS (LEUKOPAKS, 2022)
  • TABLE 234 LEUKOPAKS MARKET: DEGREE OF COMPETITION
  • FIGURE 69 LEUKOPAKS MARKET SHARE, BY KEY PLAYER (2022)
• 13.7 COMPANY EVALUATION MATRIX, 2022 (LEUKAPHERESIS PRODUCTS MARKET)
  • 13.7.1 STARS
  • 13.7.2 EMERGING LEADERS
  • 13.7.3 PERVASIVE PLAYERS
  • 13.7.4 PARTICIPANTS
  • FIGURE 70 LEUKAPHERESIS PRODUCTS MARKET: COMPANY EVALUATION MATRIX (2022)
• 13.8 COMPETITIVE EVALUATION MATRIX FOR START-UPS/SMES (LEUKAPHERESIS MARKET) (2022)
  • TABLE 235 LEUKAPHERESIS MARKET: KEY START-UPS/SMES
  • 13.8.1 PROGRESSIVE COMPANIES
  • 13.8.2 DYNAMIC COMPANIES
  • 13.8.3 STARTING BLOCKS
  • 13.8.4 RESPONSIVE COMPANIES
  • FIGURE 71 LEUKAPHERESIS MARKET: SMES/START-UPS COMPANY EVALUATION QUADRANT (2022)
• 13.9 COMPETITIVE EVALUATION MATRIX, 2022 (LEUKOPAKS MARKET)
  • 13.9.1 STARS
  • 13.9.2 EMERGING LEADERS
  • 13.9.3 PERVASIVE PLAYERS
  • 13.9.4 PARTICIPANTS
  • FIGURE 72 LEUKOPAKS MARKET: COMPANY EVALUATION MATRIX (2022)
• 13.10 COMPETITIVE SCENARIO AND TRENDS
  • TABLE 236 PRODUCT LAUNCHES AND APPROVALS (JANUARY 2019-AUGUST 2023)
  • TABLE 237 DEALS (JANUARY 2019-AUGUST 2023)
  • TABLE 238 OTHER DEVELOPMENTS (JANUARY 2019-AUGUST 2023)

14 COMPANY PROFILES

• 14.1 KEY PLAYERS (LEUKAPHERESIS PRODUCTS MARKET)
• (Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)**
• 14.1.1 TERUMO BCT
• TABLE 239 TERUMO BCT: COMPANY OVERVIEW
• FIGURE 73 TERUMO BCT: COMPANY SNAPSHOT (2022)
• 14.1.2 FRESENIUS SE & CO. KGAA
• TABLE 240 FRESENIUS SE & CO. KGAA: COMPANY OVERVIEW
• FIGURE 74 FRESENIUS SE & CO. KGAA: COMPANY SNAPSHOT (2022)
• 14.1.3 HAEMONETICS CORPORATION
• TABLE 241 HAEMONETICS CORPORATION: COMPANY OVERVIEW
• FIGURE 75 HAEMONETICS CORPORATION: COMPANY SNAPSHOT (2022)
• 14.1.4 ASAHI KASEI CORPORATION
• TABLE 242 ASAHI KASEI CORPORATION: COMPANY OVERVIEW
• FIGURE 76 ASAHI KASEI CORPORATION: COMPANY SNAPSHOT (2022)
• 14.1.5 MACOPHARMA SA
• TABLE 243 MACOPHARMA SA: COMPANY OVERVIEW
• 14.1.6 MILTENYI BIOTEC
• TABLE 244 MILTENYI BIOTEC: COMPANY OVERVIEW
• 14.2 OTHER PLAYERS (LEUKAPHERESIS PRODUCTS MARKET)
  • 14.2.1 GUANGZHOU DAJI MEDICAL SCIENCE AND TECHNOLOGY CO. LTD.
  • TABLE 245 GUANGZHOU DAJI MEDICAL SCIENCE AND TECHNOLOGY CO. LTD.: COMPANY OVERVIEW
  • 14.2.2 MEDICA SPA.
  • TABLE 246 MEDICA SPA: COMPANY OVERVIEW
  • 14.2.3 PURIBLOOD MEDICAL CO. LTD.
  • TABLE 247 PURIBLOOD MEDICAL CO. LTD.: COMPANY OVERVIEW
  • 14.2.4 BEIJING ZKSK TECHNOLOGY CO. LTD.
  • TABLE 248 BEIJING ZKSK TECHNOLOGY CO. LTD.: COMPANY OVERVIEW
  • 14.2.5 SB-KAWASUMI LABORATORIES, INC.
  • TABLE 249 SB-KAWASUMI LABORATORIES, INC.: COMPANY OVERVIEW
  • 14.2.6 NIKKISO CO., LTD.
  • TABLE 250 NIKKISO CO., LTD.: COMPANY OVERVIEW
  • FIGURE 77 NIKKISO CO., LTD.: COMPANY SNAPSHOT (2022)
  • 14.2.7 PALL CORPORATION
  • TABLE 251 PALL CORPORATION: COMPANY OVERVIEW
• 14.3 KEY PLAYERS (LEUKOPAKS MARKET)
  • 14.3.1 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
  • TABLE 252 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY OVERVIEW
  • FIGURE 78 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT (2022)
  • 14.3.2 DISCOVERY LIFE SCIENCES, INC.
  • TABLE 253 DISCOVERY LIFE SCIENCES, INC.: COMPANY OVERVIEW
  • 14.3.3 BIOIVT
  • TABLE 254 BIOIVT: COMPANY OVERVIEW
  • 14.3.4 PRECISION FOR MEDICINE, INC.
  • TABLE 255 PRECISION FOR MEDICINE, INC.: COMPANY OVERVIEW
  • 14.3.5 STEMEXPRESS, LLC
  • TABLE 256 STEMEXPRESS, LLC: COMPANY OVERVIEW
• 14.4 OTHER PLAYERS (LEUKOPAKS MARKET)
  • 14.4.1 LONZA GROUP AG
  • TABLE 257 LONZA GROUP AG: COMPANY OVERVIEW
  • FIGURE 79 LONZA GROUP AG: COMPANY SNAPSHOT (2022)
  • 14.4.2 CALTAG MEDSYSTEMS LIMITED
  • TABLE 258 CALTAG MEDSYSTEMS LIMITED: COMPANY OVERVIEW
  • 14.4.3 ZENBIO, INC.
  • TABLE 259 ZENBIO, INC.: COMPANY OVERVIEW
  • 14.4.4 STEMCELL TECHNOLOGIES
  • 14.4.5 TRINA BIOREACTIVES AG
  • 14.4.6 ACCEGEN
  • 14.4.7 FIRST CHOICE BIO LLC
• *Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.

15 APPENDIX

• 15.1 DISCUSSION GUIDE
• 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 15.3 CUSTOMIZATION OPTIONS
• 15.4 RELATED REPORTS
• 15.5 AUTHOR DETAILS